Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

IMMURON IMRN

Healthcare  —  Biotechnology
1.16 (0.01) (0.85%) as of 25 Sep
Market cap
$9.6M
P/E
0.0×
Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

IMMURON (IMRN) Business Profile

Updated before January 2025

Company Overview

Immuron Limited (NASDAQ: IMRN) is a biopharmaceutical company headquartered in Melbourne, Australia. Founded in 1994, the company specializes in the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases. Immuron’s proprietary technology leverages polyclonal antibodies derived from bovine colostrum to target specific pathogens and toxins in the gastrointestinal tract. The company is led by a team of experienced professionals, including its CEO, Steven Lydeamore, who has extensive expertise in the pharmaceutical and biotechnology sectors. Immuron operates with a mission to improve global health by addressing unmet medical needs in gastrointestinal and infectious diseases.

Core Business Segments

Immuron’s business is primarily focused on the development and commercialization of oral immunotherapeutics. The company’s product portfolio is divided into the following key segments:

1. Travel-Related Gastrointestinal Disorders

  • Travelan®: A flagship product designed to reduce the risk of travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC). Travelan® is a clinically proven, over-the-counter product that provides protection against gastrointestinal infections during travel.

2. Gut-Targeted Therapeutics

  • IMM-124E: A therapeutic candidate aimed at treating non-alcoholic steatohepatitis (NASH) and other liver-related conditions. IMM-124E is currently undergoing clinical trials and has shown promise in reducing liver inflammation and improving gut health.
  • IMM-529: A product under development for the treatment of Clostridioides difficile (C. difficile) infections. IMM-529 targets the toxins produced by C. difficile, offering a novel approach to managing this challenging condition.

3. Military and Infectious Disease Applications

  • Immuron collaborates with the U.S. Department of Defense to develop oral immunotherapeutics for military personnel. These products aim to address gastrointestinal infections and other health challenges faced by soldiers in diverse environments.

Business Model

Immuron’s business model is centered on leveraging its proprietary oral immunotherapy platform to develop and commercialize products that address unmet medical needs. The company generates revenue through the sale of its over-the-counter product, Travelan®, as well as through research and development collaborations with government agencies and pharmaceutical partners. Immuron’s approach integrates:

  • Product Commercialization: Direct sales and distribution of Travelan® in key markets, including Australia, the United States, and Canada.
  • Research Partnerships: Collaborations with organizations like the U.S. Department of Defense and the National Institute of Allergy and Infectious Diseases (NIAID) to advance its pipeline of therapeutics.
  • Licensing Opportunities: Out-licensing its technology to pharmaceutical companies for the development of new products.

Strategic Direction

Immuron is focused on expanding its product portfolio and entering new markets. Key strategic initiatives include:

  • Pipeline Expansion: Advancing clinical trials for IMM-124E and IMM-529 to address liver diseases and C. difficile infections, respectively.
  • Geographic Growth: Increasing the availability of Travelan® in emerging markets and expanding its presence in North America and Europe.
  • Sustainability Goals: Implementing environmentally friendly practices in its manufacturing processes and supply chain.
  • Innovation: Exploring new applications for its oral immunotherapy platform, including potential treatments for autoimmune diseases and other gut-mediated conditions.

Competitive Landscape

Immuron operates in a competitive biopharmaceutical market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Salix Pharmaceuticals: A leader in gastrointestinal health products.
  • Seres Therapeutics: Focused on microbiome-based therapeutics.
  • Pfizer: A global pharmaceutical giant with a diverse portfolio, including gastrointestinal treatments.
  • Ferring Pharmaceuticals: Specializes in gastroenterology and microbiome research.

Immuron differentiates itself through its proprietary oral immunotherapy platform and its focus on gut-mediated diseases.

Risk Factors

Immuron faces several risks that could impact its business operations and financial performance:

  • Market Dependence: Reliance on the success of Travelan® and its pipeline products.
  • Regulatory Challenges: Navigating complex regulatory pathways for product approvals.
  • Supply Chain Disruptions: Potential delays in manufacturing and distribution due to global supply chain issues.
  • Competition: Intense competition from larger pharmaceutical companies with greater resources.
  • Clinical Trial Risks: Uncertainty surrounding the outcomes of ongoing clinical trials.

Recent Developments

Immuron has made significant progress in recent years, including:

  • Clinical Trials: Advancing Phase II trials for IMM-124E and IMM-529, with promising preliminary results.
  • Government Collaborations: Securing funding from the U.S. Department of Defense for the development of oral immunotherapeutics for military use.
  • Product Launches: Expanding the availability of Travelan® in new markets, including Europe and Asia.
  • COVID-19 Impact: Adjusting its operations to mitigate the impact of the pandemic on clinical trials and supply chains.

Investment Considerations

Strengths:

  • Proven technology platform with broad applications.
  • Established revenue stream from Travelan® sales.
  • Strong partnerships with government agencies and research institutions.
  • Robust pipeline of innovative therapeutics.

Risks:

  • Dependence on a limited number of products for revenue.
  • High competition in the biopharmaceutical sector.
  • Regulatory and clinical trial uncertainties.
  • Potential supply chain disruptions.

Conclusion

Immuron is a pioneering biopharmaceutical company with a unique focus on oral immunotherapy for gut-mediated diseases. With a proven product in Travelan®, a promising pipeline, and strong research partnerships, the company is well-positioned for growth. However, investors should consider the risks associated with regulatory challenges, market competition, and clinical trial outcomes. Overall, Immuron’s innovative approach and strategic initiatives make it a compelling player in the biopharmaceutical industry.